ARTICLE | Company News
J&J buys single-asset anticoagulant company XO1
March 20, 2015 2:03 AM UTC
The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) acquired XO1 Ltd. (Cambridge, U.K.), a single-asset cardiovascular company developing preclinical anticoagulant ichorcumab. J&J spokesperson Ellen Rose said the company hopes to start clinical testing of the synthetic mAb against the exosite 1 region of thrombin within 18 months. Ichorcumab has the potential to provide anticoagulation without increasing the risk of bleeding (see BioCentury, July 1, 2013).
The companies did not disclose financial terms of the deal. ...